{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T02:49:27Z","timestamp":1709606967383},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Melanoma is a skin cancer with great metastatic potential, which is responsible for the major deaths in skin cancer. Although the prognosis of melanoma patients has been improved with the comprehensive treatment, for patients with metastasis, the complexity and heterogeneity of diffuse diseases make prognosis prediction and systematic treatment difficult and ineffective. Therefore, we established a novel personalized immune-related gene pairs index (IRGPI) to predict the prognosis of patients with metastatic melanoma, which was conducive to provide new insights into clinical decision-making and prognostic monitoring for metastatic melanoma. Through complex analysis and filtering, we identified 24 immune-related gene pairs to build the model and obtained the optimal cut-off value from receiver operating characteristic curves, which divided the patients into high and low immune-risk groups. Meantime, the Kaplan\u2013Meier analysis, Cox regression analysis and subgroup analysis showed that IRGPI had excellent prognostic value. Furthermore, IRGPI was shown that was closely associated with immune system in the subsequent tumor microenvironment analysis and gene set enrichment analysis. In addition, we broken through the data processing limitations of traditional researches in different platforms through the application of gene pairs, which would provide great credibility for our model. We believe that our research would provide a new perspective for clinical decision-making and prognostic monitoring in metastatic melanoma.<\/jats:p>","DOI":"10.1038\/s41598-020-80858-1","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:15:21Z","timestamp":1610536521000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of an immune-related gene pairs index for the prognosis analysis of metastatic melanoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Rong-zhi","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-qi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-you","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan-yue","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"80858_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1741-7015-10-23","volume":"10","author":"L Finn","year":"2012","unstructured":"Finn, L., Markovic, S. N. & Joseph, R. W. Therapy for metastatic melanoma: the past, present, and future. BMC Med. 10, 23. https:\/\/doi.org\/10.1186\/1741-7015-10-23 (2012).","journal-title":"BMC Med."},{"key":"80858_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","volume":"59","author":"M Marzagalli","year":"2019","unstructured":"Marzagalli, M., Ebelt, N. D. & Manuel, E. R. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin. Cancer Biol. 59, 236\u2013250. https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.002 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"80858_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.pop.2015.07.006","volume":"42","author":"MA Linares","year":"2015","unstructured":"Linares, M. A., Zakaria, A. & Nizran, P. Skin cancer. Prim. Care 42, 645\u2013659. https:\/\/doi.org\/10.1016\/j.pop.2015.07.006 (2015).","journal-title":"Prim. Care"},{"key":"80858_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 66, 271\u2013289. https:\/\/doi.org\/10.3322\/caac.21349 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"80858_CR5","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/jco.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 6199\u20136206. https:\/\/doi.org\/10.1200\/jco.2009.23.4799 (2009).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"80858_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","volume":"27","author":"N McGranahan","year":"2015","unstructured":"McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15\u201326. https:\/\/doi.org\/10.1016\/j.ccell.2014.12.001 (2015).","journal-title":"Cancer Cell"},{"key":"80858_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/s0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf, D. et al. Melanoma. Lancet (London, England) 392, 971\u2013984. https:\/\/doi.org\/10.1016\/s0140-6736(18)31559-9 (2018).","journal-title":"Lancet (London, England)"},{"key":"80858_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.coi.2013.03.004","volume":"25","author":"H Angell","year":"2013","unstructured":"Angell, H. & Galon, J. From the immune contexture to the immunoscore: The role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 25, 261\u2013267. https:\/\/doi.org\/10.1016\/j.coi.2013.03.004 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"80858_CR9","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612. https:\/\/doi.org\/10.1038\/ncomms3612 (2013).","journal-title":"Nat. Commun."},{"key":"80858_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945. https:\/\/doi.org\/10.1038\/nm.3909 (2015).","journal-title":"Nat. Med."},{"key":"80858_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/nov157","volume":"18","author":"DJ Silver","year":"2016","unstructured":"Silver, D. J., Sinyuk, M., Vogelbaum, M. A., Ahluwalia, M. S. & Lathia, J. D. The intersection of cancer, cancer stem cells, and the immune system: Therapeutic opportunities. Neuro-oncology 18, 153\u2013159. https:\/\/doi.org\/10.1093\/neuonc\/nov157 (2016).","journal-title":"Neuro-oncology"},{"key":"80858_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00109-015-1376-x","volume":"94","author":"Y Liu","year":"2016","unstructured":"Liu, Y. & Cao, X. Immunosuppressive cells in tumor immune escape and metastasis. J. Mol. Med. (Berlin, Germany) 94, 509\u2013522. https:\/\/doi.org\/10.1007\/s00109-015-1376-x (2016).","journal-title":"J. Mol. Med. (Berlin, Germany)"},{"key":"80858_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10010006","author":"N Martinez-Bosch","year":"2018","unstructured":"Martinez-Bosch, N., Vinaixa, J. & Navarro, P. Immune evasion in pancreatic cancer: From mechanisms to therapy. Cancers https:\/\/doi.org\/10.3390\/cancers10010006 (2018).","journal-title":"Cancers"},{"key":"80858_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2217\/imt.15.111","volume":"8","author":"S Valpione","year":"2016","unstructured":"Valpione, S. & Campana, L. G. Immunotherapy for advanced melanoma: Future directions. Immunotherapy 8, 199\u2013209. https:\/\/doi.org\/10.2217\/imt.15.111 (2016).","journal-title":"Immunotherapy"},{"key":"80858_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ctrv.2013.04.006","volume":"39","author":"H Gogas","year":"2013","unstructured":"Gogas, H., Polyzos, A. & Kirkwood, J. Immunotherapy for advanced melanoma: Fulfilling the promise. Cancer Treat. Rev. 39, 879\u2013885. https:\/\/doi.org\/10.1016\/j.ctrv.2013.04.006 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"80858_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40257-013-0013-0","volume":"14","author":"D Zikich","year":"2013","unstructured":"Zikich, D., Schachter, J. & Besser, M. J. Immunotherapy for the management of advanced melanoma: The next steps. Am. J. Clin. Dermatol. 14, 261\u2013272. https:\/\/doi.org\/10.1007\/s40257-013-0013-0 (2013).","journal-title":"Am. J. Clin. Dermatol."},{"key":"80858_CR17","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/(sici)1097-0142(20000501)88:9<2042::aid-cncr9>3.0.co;2-j","volume":"88","author":"AH Enk","year":"2000","unstructured":"Enk, A. H., Nashan, D., R\u00fcbben, A. & Knop, J. High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer 88, 2042\u20132046. https:\/\/doi.org\/10.1002\/(sici)1097-0142(20000501)88:9%3c2042::aid-cncr9%3e3.0.co;2-j (2000).","journal-title":"Cancer"},{"key":"80858_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature05970","volume":"448","author":"T Korn","year":"2007","unstructured":"Korn, T. et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448, 484\u2013487. https:\/\/doi.org\/10.1038\/nature05970 (2007).","journal-title":"Nature"},{"key":"80858_CR19","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1200\/jco.2011.40.0655","volume":"30","author":"TM Petrella","year":"2012","unstructured":"Petrella, T. M. et al. Interleukin-21 has activity in patients with metastatic melanoma: A phase II study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30, 3396\u20133401. https:\/\/doi.org\/10.1200\/jco.2011.40.0655 (2012).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"80858_CR20","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.4049\/jimmunol.161.7.3347","volume":"161","author":"ML Alegre","year":"1998","unstructured":"Alegre, M. L., Shiels, H., Thompson, C. B. & Gajewski, T. F. Expression and function of CTLA-4 in Th1 and Th2 cells. J. Immunol. (Baltimore, Md.: 1950) 161, 3347\u20133356 (1998).","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"80858_CR21","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, N.Y.) 271, 1734\u20131736. https:\/\/doi.org\/10.1126\/science.271.5256.1734 (1996).","journal-title":"Science (New York, N.Y.)"},{"key":"80858_CR22","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690 (2012).","journal-title":"N. Engl. J. Med."},{"key":"80858_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2017.1609","volume":"3","author":"B Li","year":"2017","unstructured":"Li, B., Cui, Y., Diehn, M. & Li, R. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol. 3, 1529\u20131537. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1609 (2017).","journal-title":"JAMA Oncol."},{"key":"80858_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112. https:\/\/doi.org\/10.1038\/nature08460 (2009).","journal-title":"Nature"},{"key":"80858_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118 (2012).","journal-title":"OMICS"},{"key":"80858_CR26","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41416-018-0296-2","volume":"119","author":"V Gunda","year":"2018","unstructured":"Gunda, V. et al. Combinations of BRAF inhibitor and anti-PD-1\/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br. J. Cancer 119, 1223\u20131232. https:\/\/doi.org\/10.1038\/s41416-018-0296-2 (2018).","journal-title":"Br. J. Cancer"},{"key":"80858_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1590\/abd1806-4841.20176183","volume":"92","author":"MH Giavina-Bianchi","year":"2017","unstructured":"Giavina-Bianchi, M. H., Giavina-Bianchi, P. F. J. & Festa, C. N. Melanoma: tumor microenvironment and new treatments. Anais Bras. Dermatol. 92, 156\u2013166. https:\/\/doi.org\/10.1590\/abd1806-4841.20176183 (2017).","journal-title":"Anais Bras. Dermatol."},{"key":"80858_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/pcmr.12661","volume":"31","author":"GM Fischer","year":"2018","unstructured":"Fischer, G. M. et al. Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell Melanoma .earch 31, 11\u201330. https:\/\/doi.org\/10.1111\/pcmr.12661 (2018).","journal-title":"Pigment Cell Melanoma .earch"},{"key":"80858_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40425-017-0229-2","volume":"5","author":"JW Smithy","year":"2017","unstructured":"Smithy, J. W. et al. Nuclear IRF-1 expression as a mechanism to assess \u201cCapability\u201d to express PD-L1 and response to PD-1 therapy in metastatic melanoma. J. Immunother. Cancer 5, 25. https:\/\/doi.org\/10.1186\/s40425-017-0229-2 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"80858_CR30","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.ccr-18-0309","volume":"24","author":"DB Johnson","year":"2018","unstructured":"Johnson, D. B. et al. Quantitative spatial profiling of PD-1\/PD-L1 interaction and HLA-DR\/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 24, 5250\u20135260. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-0309 (2018).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"80858_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060613","author":"N Reynders","year":"2019","unstructured":"Reynders, N. et al. The distinct roles of CXCR3 variants and their ligands in the tumor microenvironment. Cells https:\/\/doi.org\/10.3390\/cells8060613 (2019).","journal-title":"Cells"},{"key":"80858_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.canlet.2007.10.021","volume":"259","author":"MN Wente","year":"2008","unstructured":"Wente, M. N. et al. CXCL14 expression and potential function in pancreatic cancer. Cancer Lett. 259, 209\u2013217. https:\/\/doi.org\/10.1016\/j.canlet.2007.10.021 (2008).","journal-title":"Cancer Lett."},{"key":"80858_CR33","first-page":"5599","volume":"34","author":"J Waisberg","year":"2014","unstructured":"Waisberg, J. et al. Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer. Anticancer Res. 34, 5599\u20135607 (2014).","journal-title":"Anticancer Res."},{"key":"80858_CR34","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/cas.13931","volume":"110","author":"JS Chen","year":"2019","unstructured":"Chen, J. S. et al. PIK3CD induces cell growth and invasion by activating AKT\/GSK-3\u03b2\/\u03b2-catenin signaling in colorectal cancer. Cancer Sci. 110, 997\u20131011. https:\/\/doi.org\/10.1111\/cas.13931 (2019).","journal-title":"Cancer Sci."},{"key":"80858_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12967-020-02235-w","volume":"18","author":"NAN Jorge","year":"2020","unstructured":"Jorge, N. A. N. et al. Poor clinical outcome in metastatic melanoma is associated with a microRNA-modulated immunosuppressive tumor microenvironment. J. Transl. Med. 18, 56. https:\/\/doi.org\/10.1186\/s12967-020-02235-w (2020).","journal-title":"J. Transl. Med."},{"key":"80858_CR36","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1158\/1078-0432.ccr-10-1297","volume":"16","author":"ME Dudley","year":"2010","unstructured":"Dudley, M. E. et al. CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 16, 6122\u20136131. https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-1297 (2010).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"80858_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.can-13-1186","volume":"74","author":"AI Romero","year":"2014","unstructured":"Romero, A. I. et al. Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R\u03b1 and NKG2D triggering. Can. Res. 74, 68\u201380. https:\/\/doi.org\/10.1158\/0008-5472.can-13-1186 (2014).","journal-title":"Can. Res."},{"key":"80858_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1365-2133.2008.08709.x","volume":"159","author":"DS Green","year":"2008","unstructured":"Green, D. S., Dalgleish, A. G., Belonwu, N., Fischer, M. D. & Bodman-Smith, M. D. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1\/Th2 balance in patients with metastatic melanoma. Br. J. Dermatol. 159, 606\u2013614. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08709.x (2008).","journal-title":"Br. J. Dermatol."},{"key":"80858_CR39","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/1078-0432.ccr-12-1947","volume":"19","author":"K Saga","year":"2013","unstructured":"Saga, K., Tamai, K., Yamazaki, T. & Kaneda, Y. Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-\u03b3 production. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 19, 668\u2013679. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-1947 (2013).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"80858_CR40","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1097\/CJI.0b013e3181fb045d","volume":"33","author":"LT Dengel","year":"2010","unstructured":"Dengel, L. T. et al. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J. Immunother. (Hagerstown, Md.: 1997) 33, 965\u2013974. https:\/\/doi.org\/10.1097\/CJI.0b013e3181fb045d (2010).","journal-title":"J. Immunother. (Hagerstown, Md.: 1997)"},{"key":"80858_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2407-14-118","volume":"14","author":"S Pinto","year":"2014","unstructured":"Pinto, S. et al. Intracellular coexpression of CXC- and CC- chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation. BMC Cancer 14, 118. https:\/\/doi.org\/10.1186\/1471-2407-14-118 (2014).","journal-title":"BMC Cancer"},{"key":"80858_CR42","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1001\/jamaoncol.2017.3808","volume":"4","author":"WL Hwang","year":"2018","unstructured":"Hwang, W. L. et al. Clinical outcomes in patients with metastatic lung cancer treated with PD-1\/PD-L1 Inhibitors and thoracic radiotherapy. JAMA Oncol. 4, 253\u2013255. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3808 (2018).","journal-title":"JAMA Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80858-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80858-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80858-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T14:38:20Z","timestamp":1697553500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80858-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80858"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80858-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1253"}}